skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification of cancer stem cell markers in human malignant mesothelioma cells

Abstract

Research highlights: {yields} We performed serial transplantation of surgical samples and established new cell lines of malignant mesothelioma. {yields} SP cell and expressions of CD9/CD24/CD26 were often observed in mesothelioma cell lines. {yields} SP and CD24{sup +} cells proliferated by asymmetric cell division-like manner. CD9{sup +} and CD24{sup +} cells have higher potential to generate spheroid colony. {yields} The marker-positive cells have clear tendency to generate larger tumors in mice. -- Abstract: Malignant mesothelioma (MM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells and usually associated with long-term asbestos exposure. Recent studies suggest that tumors contain cancer stem cells (CSCs) and their stem cell characteristics are thought to confer therapy-resistance. However, whether MM cell has any stem cell characteristics is not known. To understand the molecular basis of MM, we first performed serial transplantation of surgical samples into NOD/SCID mice and established new cell lines. Next, we performed marker analysis of the MM cell lines and found that many of them contain SP cells and expressed several putative CSC markers such as CD9, CD24, and CD26. Interestingly, expression of CD26 closely correlated with that of CD24 in some cases. Sorting and culture assay revealed that SPmore » and CD24{sup +} cells proliferated by asymmetric cell division-like manner. In addition, CD9{sup +} and CD24{sup +} cells have higher potential to generate spheroid colony than negative cells in the stem cell medium. Moreover, these marker-positive cells have clear tendency to generate larger tumors in mouse transplantation assay. Taken together, our data suggest that SP, CD9, CD24, and CD26 are CSC markers of MM and could be used as novel therapeutic targets.« less

Authors:
; ; ;  [1]; ; ;  [2]; ;  [3];  [4];  [5];  [1]
  1. Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo (Japan)
  2. Departments of Medical Oncology, Yamaguchi-Ube Medical Center, Yamaguchi (Japan)
  3. Department of Respiratory Medicine, Okayama Rosai Hospital, Okayama (Japan)
  4. Department of Pathology, Keio University School of Medicine, Tokyo (Japan)
  5. Drug Development Program, Nevada Cancer Institute, Las Vegas, NV (United States)
Publication Date:
OSTI Identifier:
22204759
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 404; Journal Issue: 2; Other Information: Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ASBESTOS; ASYMMETRY; CELL DIVISION; MICE; NEOPLASMS; SPHEROIDS; STEM CELLS; SURGERY

Citation Formats

Ghani, Farhana Ishrat, Yamazaki, Hiroto, Iwata, Satoshi, Okamoto, Toshihiro, Aoe, Keisuke, Okabe, Kazunori, Mimura, Yusuke, Fujimoto, Nobukazu, Kishimoto, Takumi, Yamada, Taketo, Xu, C. Wilson, Morimoto, Chikao, and Drug Development Program, Nevada Cancer Institute, Las Vegas, NV. Identification of cancer stem cell markers in human malignant mesothelioma cells. United States: N. p., 2011. Web. doi:10.1016/J.BBRC.2010.12.054.
Ghani, Farhana Ishrat, Yamazaki, Hiroto, Iwata, Satoshi, Okamoto, Toshihiro, Aoe, Keisuke, Okabe, Kazunori, Mimura, Yusuke, Fujimoto, Nobukazu, Kishimoto, Takumi, Yamada, Taketo, Xu, C. Wilson, Morimoto, Chikao, & Drug Development Program, Nevada Cancer Institute, Las Vegas, NV. Identification of cancer stem cell markers in human malignant mesothelioma cells. United States. https://doi.org/10.1016/J.BBRC.2010.12.054
Ghani, Farhana Ishrat, Yamazaki, Hiroto, Iwata, Satoshi, Okamoto, Toshihiro, Aoe, Keisuke, Okabe, Kazunori, Mimura, Yusuke, Fujimoto, Nobukazu, Kishimoto, Takumi, Yamada, Taketo, Xu, C. Wilson, Morimoto, Chikao, and Drug Development Program, Nevada Cancer Institute, Las Vegas, NV. 2011. "Identification of cancer stem cell markers in human malignant mesothelioma cells". United States. https://doi.org/10.1016/J.BBRC.2010.12.054.
@article{osti_22204759,
title = {Identification of cancer stem cell markers in human malignant mesothelioma cells},
author = {Ghani, Farhana Ishrat and Yamazaki, Hiroto and Iwata, Satoshi and Okamoto, Toshihiro and Aoe, Keisuke and Okabe, Kazunori and Mimura, Yusuke and Fujimoto, Nobukazu and Kishimoto, Takumi and Yamada, Taketo and Xu, C. Wilson and Morimoto, Chikao and Drug Development Program, Nevada Cancer Institute, Las Vegas, NV},
abstractNote = {Research highlights: {yields} We performed serial transplantation of surgical samples and established new cell lines of malignant mesothelioma. {yields} SP cell and expressions of CD9/CD24/CD26 were often observed in mesothelioma cell lines. {yields} SP and CD24{sup +} cells proliferated by asymmetric cell division-like manner. CD9{sup +} and CD24{sup +} cells have higher potential to generate spheroid colony. {yields} The marker-positive cells have clear tendency to generate larger tumors in mice. -- Abstract: Malignant mesothelioma (MM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells and usually associated with long-term asbestos exposure. Recent studies suggest that tumors contain cancer stem cells (CSCs) and their stem cell characteristics are thought to confer therapy-resistance. However, whether MM cell has any stem cell characteristics is not known. To understand the molecular basis of MM, we first performed serial transplantation of surgical samples into NOD/SCID mice and established new cell lines. Next, we performed marker analysis of the MM cell lines and found that many of them contain SP cells and expressed several putative CSC markers such as CD9, CD24, and CD26. Interestingly, expression of CD26 closely correlated with that of CD24 in some cases. Sorting and culture assay revealed that SP and CD24{sup +} cells proliferated by asymmetric cell division-like manner. In addition, CD9{sup +} and CD24{sup +} cells have higher potential to generate spheroid colony than negative cells in the stem cell medium. Moreover, these marker-positive cells have clear tendency to generate larger tumors in mouse transplantation assay. Taken together, our data suggest that SP, CD9, CD24, and CD26 are CSC markers of MM and could be used as novel therapeutic targets.},
doi = {10.1016/J.BBRC.2010.12.054},
url = {https://www.osti.gov/biblio/22204759}, journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 2,
volume = 404,
place = {United States},
year = {Fri Jan 14 00:00:00 EST 2011},
month = {Fri Jan 14 00:00:00 EST 2011}
}